Introduction
Left ventricular hypertrophy (LVH) is a frequent and well-recognized consequence of a chronically elevated blood pressure (BP). Several studies have demonstrated that LVH is an independent cardiovascular risk factor, associated with an increased likelihood to develop cardiovascular complications such as congestive heart failure, sudden cardiac death, coronary heart disease and stroke [1, 2] . Conversely, an aggressive treatment of hypertension can prevent and reverse LVH and reduce the incidence of cardiovascular events [3, 4] .
Non-haemodynamic factors leading to LVH
If BP is definitively the major trigger for the development of cardiac hypertrophy in hypertension, left ventricular mass may be affected by several other non-haemodynamic factors which may also play an important role in the pathophysiology of LVH, as listed in Table 1 . Factors such as gender, age, race, obesity, alcohol consumption, catecholamines, ANP, aldosterone and angiotensin II and genetic factors (polymorphism of ACE) have all been considered as BP-independent determinants of left ventricular structure. However, in clinical conditions, it is often difficult to demonstrate that the effect of these factors is really independent of BP, because small but long-standing changes in BP, which may contribute to the development of LVH may be missed, such as for example, nighttime increases in BP. Indeed, the discrimination between normotension and hypertension is arbitrary and a loss of the normal nocturnal decline in BP has been associated with an increased incidence of LVH [5] . Similarly, an excessive rise in BP may induce LVH in subjects who participate in vigorous but unsustained exercises.
Experimental studies in transgenic mice have sometimes provided good evidence that some of these factors induce cardiac hypertrophy, independently of changes in systemic BP. For example, the overexpression of angiotensinogen in cardiomyocytes leads to an increased production of angiotensin II limited to the heart with normal plasma levels [6] . Interestingly, these transgenic mice develop a marked cardiac hypertrophy in the absence of systemic hypertension and the increase in cardiac mass could be prevented by the administration of a blocker of the angiotensin II AT1 receptor [6] . In another transgenic mice model, inactivation of the guanylyl-cyclase-A gene selectively in the heart has been found to exhibit a mild cardiac hypertrophy, a marked increase in mRNA expression of cardiac hypertrophy markers, but a 7-10 mmHg lower BP than control mice [7] . In some experiments, a regression of LVH was found without a decrease in BP [8, 9] . For example, non-selective blockade of endothelin receptors with bosentan has been found to lower cardiac hypertrophy without lowering BP [8] . A similar observation was made with the inhibition of the transcription nuclear factor (NF)-kB in spontaneously hypertensive rats [9] . Taken together, these experimental data suggest that there are definite mechanisms which contribute to the development of cardiac hypertrophy independently of BP, but their role in humans remains to be demonstrated.
Does sodium have a role in the development of LVH?
There is also increasing evidence that a high salt intake may have deleterious effects on the cardiovascular system and lead to the development of cardiac and vascular hypertrophy, independently or in addition to its effect on BP [10] [11] [12] . However, once again, it is difficult to ascertain whether the impact of the high sodium intake on cardiac mass or vascular hypertrophy really is independent of BP, unless this latter is measured carefully over 24 h, which was not the case in these studies. Indeed, BP during sleeping hours may be crucial for the development of LVH even in animals [13] .
In rats, increasing the sodium content of the diet often increases BP but there are some reports suggesting that sodium may induce LVH even in normotensive animals [14] . We recently investigated the combined effects of sodium and mineralocorticoids on BP and cardiac and renal hypertrophy in two strains of mice, one carrying one renin gene (the Ren-1 c gene) and a second one carrying two renin genes, i.e. the Ren-1 d and the Ren-2 genes [15] . The major difference between these two strains is that the tworenin gene mice exhibit a 10-fold higher plasma renin activity and a 100-fold higher plasma renin concentration, which are not suppressed by a high sodium intake. Two-renin gene mice are salt sensitive and have a higher baseline BP. When these mice are uninephrectomized and receive a 1% sodium diet together with deoxycorticosterone for several weeks, their BP increases markedly and they develop a significant cardiac hypertrophy and an increase in the mass of the remaining kidney. To our surprise, mice with only one renin gene exhibited no increase in BP when receiving DOCA/salt. However, these animals also develop cardiac and renal hypertrophy. These data therefore suggested that sodium, when added to a high dose of mineralocorticoids, could contribute to induce cardiac and renal hypertrophy, even in the absence of BP changes [15] . To further investigate the respective role of mineralocorticoids and sodium in the development of cardiac hypertrophy, the same onerenin gene mice were treated for 4 weeks with DOCA and either a low or a high sodium diet [16] . Interestingly, mice receiving DOCA and a low sodium diet develop all the signs of hypermineralocorticism but no significant increase in cardiac mass ( Figure 1 ). These data indicate that an excess of mineralocorticoid per se is not sufficient to induce cardiac and renal hypertrophy and the presence of a high sodium intake is a necessary condition for the development of mineralocorticoid-induced cardiac and renal damages.
To further explore the role of mineralocorticoids and sodium in the development of cardiac hypertrophy, we examined the direct consequences of chronically elevated plasma aldosterone levels on cardiac mass in a mouse model (a epithelium Na channel -/-Tg), which is normotensive under a normal sodium diet but exhibits chronic hyperaldosteronism [17] . After birth, these mice develop a pseudohypoaldosteronism type 1 (PHA-1) characterized by a metabolic acidosis, urinary salt wasting and growth retardation. Within 2 weeks after birth 50% of these mice die, but the survivors develop a compensated state of PHA-1 with a normal acid-base status, a compensated salt wasting and 6-fold higher plasma aldosterone levels than control. These mice and their control were examined after 16 months of life. We found that despite chronically elevated aldosterone levels and a low BP, these mice had no evidence of cardiac hypertrophy, remodelling or fibrosis [17] . Therefore, this observation suggests that hypermineralocorticism does not induce cardiac hypertrophy in mice with a urinary salt wasting phenotype. This further emphasizes the importance of sodium as an important cofactor for the development of cardiac hypertrophy and that a hypermineralocorticism per se has little if any effect on the heart, unless animals receive a high sodium intake.
In more recent studies, we have shown that metabolic factors other than sodium may contribute to the development of cardiac hypertrophy in the DOCA/salt mice model. Indeed, the DOCA/salt model is characterized by the development of hypokalaemia and metabolic alkalosis. We demonstrated that these two factors may also participate in the 
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Cardiac weight index(mg/g) Fig. 1 . Effect of a high and low sodium diet on cardiac weight index in deoxycorticosterone-treated mice. BP was normal and comparable in all groups. Cardiac hypertrophy was found in one-renin gene mice receiving DOCA and a high salt intake (1% NaCl in the drinking water). No cardiac hypertrophy was observed on a low sodium diet (0.5 mg Na/g food). Adapted from references 14 and 15.
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pathophysiology of cardiac hypertrophy, as correction of the hypokalaemia can prevent the development of cardiac hypertrophy without affecting BP [18] . These data suggest that there might be an interaction between the high-salt intake and the mineralocorticoid-induced loss of potassium to trigger hypertrophic factors leading to cardiac hypertrophy. Yet, other factors may contribute to the development of LVH in the mineralocorticoid-salt-induced model, including the alkalosis itself and the development of hypomagnesaemia, which has also been reported to accompany mineralocorticoid excess and to interact negatively on heart function with the development of hypokalaemia [19] .
What is the normal BP in mice with cardiac hypertrophy?
The development of cardiac hypertrophy in the presence of a so-called 'normal' BP might raise the question of the normality of BP. One could postulate that there is a resetting of the BP/cardiac hypertrophicresponse relationship and that in this situation a lower BP could perhaps prevent the occurrence of cardiac hypertrophy. To test this hypothesis, we recently treated normotensive DOCA/salt mice with a calcium channel blocker, in order to lower their 'normal' BP and to assess the impact of lower BP on cardiac hypertrophy. To our surprise, reducing BP in these mice was associated with a reduction in cardiac mass, as shown in Figure 2 [20] . These results would thus suggest that there is indeed a resetting and that in the presence of LVH, one should perhaps aim at a lower BP.
Conclusions
LVH is an independent risk factor for the development of cardiovascular complications in hypertensive patients. Although BP is the major trigger for the development of LVH, several non-haemodynamic factors should also be taken into account, including sodium and potassium intake. Recent animal data have indeed suggested that a high sodium intake is a crucial cofactor contributing to the pathophysiology of cardiac hypertrophy, particularly in situations of mineralocorticoid excess. These observations further emphasize the importance of nonpharmacological recommendations in the management of hypertensive patients, in order to prevent target organ damages. 
Introduction
Iron deficiency is a frequent complication in patients with chronic kidney disease (CKD). Major causes are reduced dietary intake, impaired absorption, chronic blood loss, inflammatory or infectious comorbidity and increased requirements during correction of renal anaemia with erythropoiesis-stimulating agents (ESA).
Inadaequate iron stores with reduced availability of iron to the bone marrow are the main cause of hyporesponsiveness to ESA treatment. Thus, in the vast majority of haemodialysis patients, intravenous iron is used in combination with ESA to treat renal anaemia. Optimal iron management, therefore, includes the monitoring of iron status and the supplementation of adaequate amounts of iron, to maintain haemoglobin levels at target in a costeffective manner [1] .
Monitoring iron status
Ferritin Serum ferritin is a parameter of iron storage in the reticuloendothelial system. In subjects without kidney disease, a value below 15 ng/ml indicates absolute iron deficiency [2] . In CKD patients, absolute iron
